کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5664060 | 1590703 | 2017 | 12 صفحه PDF | دانلود رایگان |
- EGFR inhibitors are better tolerated than chemotherapy but have specific toxicities.
- Healthcare professionals must be aware of these characteristic adverse events.
- Key prophylactic measures should be followed for patients receiving EGFR inhibitors.
- Patient/caregiver education is essential for adherence to prophylactic measures.
- Management of toxicities should be stepwise, based on the severity of symptoms.
The epidermal growth factor receptor (EGFR) is involved in development and progression of some gastrointestinal cancers, and is targeted by monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) used to treat these conditions. Targeted agents are generally better tolerated than conventional chemotherapy, but have characteristic toxicities that can affect adherence, dosing, and outcomes. Skin conditions are the most common toxicities associated with EGFR inhibitors, particularly papulopustular rash. Other common toxicities include mucosal toxicity, electrolyte imbalances (notably hypomagnesaemia), and diarrhoea, while the chimaeric mAb cetuximab is also associated with increased risk of infusion reactions. With appropriate prophylaxis, the incidence and severity of these events can be reduced, while management strategies tailored to the patient and the degree of toxicity can help to ensure continuation of anti-cancer therapy. Here, we review the main toxicities associated with EGFR-inhibiting mAbs and TKIs in patients with gastrointestinal cancers, and provide recommendations for prophylaxis and treatment.
Journal: Critical Reviews in Oncology/Hematology - Volume 114, June 2017, Pages 102-113